Oncolytics Biotech announced the completion of patient enrollment for its GOBLET Phase 1/2 study, focusing on pelareorep combined with checkpoint inhibitors for gastrointestinal cancers. The company expects final results from Cohort 4 by Q4 2026 and initial results from Cohort 5 in the first half of 2027. This milestone also triggers the final payment from the Pancreatic Cancer Action Network (PanCAN). The data will guide Oncolytics' strategy to develop pelareorep-based therapies further, especially for pancreatic and anal cancers, where early results show promising survival outcomes.
Oncolytics Biotech's update on its GOBLET study clinical data and PanCAN grant payment comes with Pluang's Health sector snapshot as of Oct 14, 2026 20:11 WIB: of 150 priced Health-sector US stocks tradable on Pluang, 73 rose and 68 fell today. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 10.03 with a 1-day change of +2.24% and 100% buy order activity, Recursion Pharmaceuticals Inc (RXRX) at USD 3.75 down 2.22% with 93% buy orders, and DENTSPLY SIRONA Inc (XRAY) at USD 8.69 up 2.18%, with a typical hold time on Pluang of 72 days.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
